[Bortezomib-based combination therapy for newly diagnosed multiple myeloma]

Area of Science:

• Hematology
• Oncology
• Clinical Pharmacology

Background:

• Multiple myeloma is a hematologic malignancy characterized by uncontrolled proliferation of plasma cells.
• Standard induction regimens for newly diagnosed multiple myeloma include vincristine, adriamycin, and dexamethasone (VAD).
• Novel therapeutic agents are continuously being investigated to improve treatment outcomes.

Purpose of the Study:

• To retrospectively compare the efficacy and safety of bortezomib-based regimens (VD/VT) versus VAD in untreated multiple myeloma patients.
• To evaluate response rates and adverse events associated with each treatment arm.

Main Methods:

• Retrospective analysis of 18 patients treated with bortezomib-based regimens (VD/VT) and 24 patients treated with VAD.
• Bortezomib regimens involved bortezomib (1.0 or 1.3 mg/m2) with dexamethasone or thalidomide.
• VAD regimen included vincristine, adriamycin, and dexamethasone over 28-day cycles.

Main Results:

• Bortezomib-based regimens achieved an overall response rate of 88.9% (16/18 patients), with 38.9% (7/18) achieving complete or near-complete response.
• Side effects in the VD/VT group were manageable, primarily hematologic, gastrointestinal, and peripheral neuropathic.
• The VAD group experienced side effects including infections, hair loss, and phlebitis.

Conclusions:

• Bortezomib-based combination therapy is an effective and safe induction regimen for newly diagnosed multiple myeloma.
• This regimen demonstrates significant superiority over VAD, achieving high response rates.
• Bortezomib-based therapy shows promise even in patients with poor prognostic features.